 |
Melbourne, June 14, 2011 (ABN Newswire) - Global regenerative medicine company, Mesoblast Limited (
ASX:MSB) (PINK:MBLTY), was featured today at the 8th Nomura Asia Equity Forum being held in Singapore. Mesoblast was the only Australian company to present at the respected Asian investor forum.
Investors were provided with clinical and commercial updates on Mesoblast's advances using its proprietary adult stem cell technology platform. Of particular focus was the progress in Mesoblast's three key product franchises for cardiovascular, spinal orthopedic, and inflammatory conditions, as well as the company's timely progression towards a Phase 3 clinical trial of its product for augmenting bone marrow transplantation in cancer patients.
Mesoblast highlighted the massive revenue potential of its cardiovascular product franchise. The outstanding Phase 2 results of Revascor(TM) in congestive heart failure were featured, as well as recent mechanistic data showing that the product improves blood flow in ischemic heart muscle. Together, these results underscore the potential of Revascor(TM) for the treatment of congestive heart failure, acute myocardial infarction, chronic refractory angina, and an increasing population of patients with vascular heart disease.
The investor forum was updated on Mesoblast's spinal orthopedic franchise targeting multiple conditions with major unmet clinical need. Investors were told that a Phase 2 trial for repair of degenerating intervertebral discs was due to commence shortly, and that the cervical and lumbar fusion Phase 2 clinical trials remain on track.
Finally, the company provided investors with strategic focus on a new intravenously delivered product franchise for a range of inflammatory conditions such as diabetes, lung disorders, and joint conditions, as well as inflammatory neurological conditions such as Multiple Sclerosis.
The slide presentation can be viewed here: http://www.abnnewswire.net/media/en/docs/356338.pdf
ASX:MSB) (PINK:MBLTY), was featured today at the 8th Nomura Asia Equity Forum being held in Singapore. Mesoblast was the only Australian company to present at the respected Asian investor forum.Investors were provided with clinical and commercial updates on Mesoblast's advances using its proprietary adult stem cell technology platform. Of particular focus was the progress in Mesoblast's three key product franchises for cardiovascular, spinal orthopedic, and inflammatory conditions, as well as the company's timely progression towards a Phase 3 clinical trial of its product for augmenting bone marrow transplantation in cancer patients.
Mesoblast highlighted the massive revenue potential of its cardiovascular product franchise. The outstanding Phase 2 results of Revascor(TM) in congestive heart failure were featured, as well as recent mechanistic data showing that the product improves blood flow in ischemic heart muscle. Together, these results underscore the potential of Revascor(TM) for the treatment of congestive heart failure, acute myocardial infarction, chronic refractory angina, and an increasing population of patients with vascular heart disease.
The investor forum was updated on Mesoblast's spinal orthopedic franchise targeting multiple conditions with major unmet clinical need. Investors were told that a Phase 2 trial for repair of degenerating intervertebral discs was due to commence shortly, and that the cervical and lumbar fusion Phase 2 clinical trials remain on track.
Finally, the company provided investors with strategic focus on a new intravenously delivered product franchise for a range of inflammatory conditions such as diabetes, lung disorders, and joint conditions, as well as inflammatory neurological conditions such as Multiple Sclerosis.
The slide presentation can be viewed here: http://www.abnnewswire.net/media/en/docs/356338.pdf
| Tweet |
About Mesoblast Limited
Mesoblast Limited (ASX:MSB) (OTC ADR: MBLTY) is the world's leading developer of innovative biological products for the broad field of regenerative medicine.
Mesoblast's commercial strategy is based on its unique proprietary adult mesenchymal precursor cells.
The company's lead products will target cardiovascular conditions, diabetes, inflammatory conditions of lungs and joints, eye diseases, bone marrow cancers, bone fractures, cartilage degeneration and musculoskeletal conditions.
Mesoblast and global biopharmaceutical company Cephalon Inc. have established a strategic alliance to commercialize adult stem cell products for degenerative conditions of the cardiovascular and central nervous systems. The alliance also extends to products for augmenting bone marrow transplantation in cancer patients.
|
||
|
 |
Related Companies |
>>>       Mesoblast Limited |
| |
Related Industry Topics: |
Biotech | Financial General | Health & Pharm General | |
| |
This Page Viewed: (Last 7 Days: 80) (Last 30 Days: 420) (Since Published: 13890) |
Events & Exhibitions
|
Site Search
| ENGLISH All Languages |
Upcoming WebCasts
 | Mr Mark Paton CEO Cue Energy Resources Tuesday, June 12, 2012 |
 | Mr Alan Hopkins CEO Pan Asia Corporation Tuesday, June 12, 2012 |
 | Mr Barry Dawes Martin Place Securities Tuesday, June 12, 2012 |
 | Dr Andrea Grant CEO Living Cell Technologies Monday, July 02, 2012 |
Companies in the News
Mobile Video TV
|
||
|
||
){kind=link}